A detailed history of Pnc Financial Services Group, Inc. transactions in Arvinas, Inc. stock. As of the latest transaction made, Pnc Financial Services Group, Inc. holds 4,443 shares of ARVN stock, worth $79,618. This represents 0.0% of its overall portfolio holdings.

Number of Shares
4,443
Previous 2,741 62.09%
Holding current value
$79,618
Previous $72,000 51.39%
% of portfolio
0.0%
Previous 0.0%

Shares

16 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 08, 2024

BUY
$23.66 - $32.73 $40,269 - $55,706
1,702 Added 62.09%
4,443 $109,000
Q2 2024

Aug 09, 2024

BUY
$24.46 - $40.4 $65,014 - $107,383
2,658 Added 3202.41%
2,741 $72,000
Q1 2024

May 10, 2024

BUY
$36.38 - $52.31 $2,510 - $3,609
69 Added 492.86%
83 $3,000
Q4 2023

Feb 09, 2024

SELL
$14.19 - $42.33 $12,941 - $38,604
-912 Reduced 98.49%
14 $0
Q3 2023

Nov 13, 2023

SELL
$19.64 - $28.21 $8,975 - $12,891
-457 Reduced 33.04%
926 $18,000
Q2 2023

Aug 11, 2023

BUY
$21.73 - $31.43 $27,358 - $39,570
1,259 Added 1015.32%
1,383 $34,000
Q1 2023

May 15, 2023

SELL
$26.15 - $37.26 $3,451 - $4,918
-132 Reduced 51.56%
124 $3,000
Q4 2022

Feb 10, 2023

BUY
$32.47 - $57.24 $4,286 - $7,555
132 Added 106.45%
256 $8,000
Q3 2022

Nov 10, 2022

BUY
$41.87 - $57.99 $2,889 - $4,001
69 Added 125.45%
124 $5,000
Q2 2022

Aug 12, 2022

SELL
$36.01 - $74.24 $1,440 - $2,969
-40 Reduced 42.11%
55 $2,000
Q1 2022

May 12, 2022

SELL
$60.27 - $81.57 $2,651 - $3,589
-44 Reduced 31.65%
95 $6,000
Q4 2021

Feb 11, 2022

BUY
$65.85 - $96.21 $658 - $962
10 Added 7.75%
139 $11,000
Q3 2021

Nov 05, 2021

BUY
$73.2 - $107.87 $4,684 - $6,903
64 Added 98.46%
129 $10,000
Q2 2021

Aug 06, 2021

BUY
$60.45 - $84.26 $846 - $1,179
14 Added 27.45%
65 $5,000
Q1 2021

May 07, 2021

SELL
$58.19 - $91.37 $11,463 - $17,999
-197 Reduced 79.44%
51 $3,000
Q2 2020

Aug 07, 2020

BUY
$29.88 - $56.74 $7,410 - $14,071
248 New
248 $8,000

Others Institutions Holding ARVN

About ARVINAS, INC.


  • Ticker ARVN
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 53,205,300
  • Market Cap $953M
  • Description
  • Arvinas, Inc., a clinical-stage biopharmaceutical company, engages in the discovery, development, and commercialization of therapies to degrade disease-causing proteins. Its lead product candidates include Bavdegalutamide, a proteolysis targeting chimera (PROTAC) protein degrader that is in phase I clinical trial targeting the androgen receptor ...
More about ARVN
Track This Portfolio

Track Pnc Financial Services Group, Inc. Portfolio

Follow Pnc Financial Services Group, Inc. and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Pnc Financial Services Group, Inc., based on Form 13F filings with the SEC.

News

Stay updated on Pnc Financial Services Group, Inc. with notifications on news.